MedTrace Logo

HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC

NCT06632106 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 97

Last updated 2024-10-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with different tumor burden advanced-stage hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).

Conditions

  • Hepatic Arterial Infusion Chemotherapy
  • Tyrosine Kinase Inhibitor
  • Immune Checkpoint Inhibitors
  • Hepatocellular Carcinoma (HCC)

Interventions

PROCEDURE

hepatic artery infusion chemotherapy

Hepatic arterial infusion chemotherapy including FOLFOX and RALOX

DRUG

Tyrosine kinase inhibitor (TKIs)

TKIs including Lenvatinib, Sorafenib, Apatinib, Donafenib, Bevacizumab

DRUG

Immune Checkpoint Inhibitors

ICIs including Camrelizumab, Sintilimab, Tislelizumab, Pembrolizumab, Atezolizumab

Sponsors & Collaborators

  • First Hospital of China Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-16
Primary Completion
2025-01-30
Completion
2025-05-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06632106 on ClinicalTrials.gov